CXCL12 signaling is independent of Jak2 and Jak3

被引:33
|
作者
Moriguchi, M
Hissong, BD
Gadina, M
Yamaoka, K
Tiffany, HL
Murphy, PM
Candotti, F
O'Shea, JJ
机构
[1] NIAMS, Mol Immunol & Inflammat Branch, NIH, Bethesda, MD 20892 USA
[2] NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA
[3] NHGRI, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1074/jbc.M414219200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Janus kinases (Jaks) are a small family of cytoplasmic tyrosine kinases, critical for signaling by Type I and II cytokine receptors. The importance of Jaks in signaling by these receptors has been firmly established by analysis of mutant cell lines, the generation of Jak knock-out mice, and the identification of patients with Jak3 mutations. While a number of other ligands that do not bind Type I and II cytokine receptors have also been reported to activate Jaks, the requirement for Jaks in signaling by these receptors is less clear. Chemokines for example, which bind seven transmembrane receptors, have been reported to activate Jaks, and principally through the use of pharmacological inhibitors, it has been argued that Jaks are essential for chemokine signaling. In the present study, we focused on CXCR4, which binds the chemokine CXCL12 or stromal cell-derived factor-1, a chemokine that has been reported to activate Jak2 and Jak3. We found that the lack of Jak3 had no effect on CXCL12 signaling or chemotaxis nor did overexpression of wild-type versions of the kinase. Similarly, overexpression of wild-type or catalytically inactive Jak2 or "knocking-down" Jak2 expression using siRNA also had no effect. We also found that in primary lymphocytes, CXCL12 did not induce appreciable phosphorylation of any of the Jaks compared with cytokines for which these kinases are required. Additionally, little or no Stat ( signal transducer and activator of transcription) phosphorylation was detected. Thus, we conclude that in contrast to previous reports, Jaks, especially Jak3, are unlikely to play an essential role in chemokine signaling.
引用
收藏
页码:17408 / 17414
页数:7
相关论文
共 50 条
  • [21] The MAPK and JAK3 signaling pathways in mastocytosis
    Chan, I
    Kayashima, K
    Tharp, M
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2002, 119 (01) : 282 - 282
  • [22] Involvement of JAK1, JAK2, and JAK3 in Stimulation of Functional Activity of Mesenchymal Progenitor Cells by Fibroblast Growth Factor
    Zyuz'kov, G. N.
    Zhdanov, V. V.
    Udut, E. V.
    Miroshnichenko, L. A.
    Simanina, E. V.
    Polyakova, T. Yu.
    Stavrova, L. A.
    Udut, V. V.
    Minakova, M. Yu.
    Dygai, A. M.
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2016, 162 (02) : 240 - 243
  • [23] Involvement of JAK1, JAK2, and JAK3 in Stimulation of Functional Activity of Mesenchymal Progenitor Cells by Fibroblast Growth Factor
    G. N. Zyuz’kov
    V. V. Zhdanov
    E. V. Udut
    L. A. Miroshnichenko
    E. V. Simanina
    T. Yu. Polyakova
    L. A. Stavrova
    V. V. Udut
    M. Yu. Minakova
    A. M. Dygai
    Bulletin of Experimental Biology and Medicine, 2016, 162 : 240 - 243
  • [24] Molecular basis of JAK2 activation in erythropoietin receptor and pathogenic JAK2 signaling
    Abraham, Bobin George
    Haikarainen, Teemu
    Vuorio, Joni
    Girych, Mykhailo
    Virtanen, Anniina T.
    Kurttila, Antti
    Karathanasis, Christos
    Heilemann, Mike
    Sharma, Vivek
    Vattulainen, Ilpo
    Silvennoinen, Olli
    SCIENCE ADVANCES, 2024, 10 (10)
  • [25] In Vitro and in Vivo Inhibition of JAK2 Signaling by Potent and Selective JAK2 Inhibitor
    Markovtsov, Vadim
    Tonkin, Elizabeth
    Fang, Shuling
    Liu, Chiang
    Gelman, Marina
    Lang, Wayne
    Romero, Jason
    McLaughlin, John
    Bhamidipati, Somasekhar
    Clough, Jeffrey
    Singh, Rajinder
    Low, Caroline
    Reitsma, Andrea
    Taylor, Vanessa
    Siu, Stacey
    Park, Gary
    Sweeney, David
    Pine, Polly
    Torneros, Allan
    Clemens, George
    Duan, Matt
    Daniel, Ruby
    Payan, Donald
    Holland, Sacha
    Hitoshi, Yasumichi
    BLOOD, 2008, 112 (11) : 1276 - 1276
  • [26] Expression, purification, characterization and crystallization of non- and phosphorylated states of JAK2 and JAK3 kinase domain
    Hall, Troii
    Emmons, Thomas L.
    Chrencik, Jill E.
    Gormley, Jennifer A.
    Weinberg, Robin A.
    Leone, Joseph W.
    Hirsch, Jeffrey L.
    Saabye, Matthew J.
    Schindler, John F.
    Day, Jacqueline E.
    Williams, Jennifer M.
    Kiefer, James R.
    Lightle, Sandra A.
    Harris, Melissa S.
    Guru, Siradanahalli
    Fischer, H. David
    Tomasselli, Alfredo G.
    PROTEIN EXPRESSION AND PURIFICATION, 2010, 69 (01) : 54 - 63
  • [27] MEDI 120-Development of novel and potent inhibitors of JAK2: Structure activity relationship studies for optimiziation of JAK2 potency while minimizing JAK3 activity
    Reddy, Venkata J.
    Mereddy, Venkatram R.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233 : 895 - 895
  • [28] Jak3 is essential for common cytokine receptor gamma chain (gc)-dependent signaling: Comparative analysis of gc, Jak3, and gc and Jak3 double deficient mice
    Suzuki, K
    Nakajima, H
    Saito, Y
    Saito, T
    Leonard, W
    Iwamoto, I
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2000, 105 (01) : S217 - S217
  • [29] Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3
    Malerich, Jeremiah P.
    Lam, Jennifer S.
    Hart, Barry
    Fine, Richard M.
    Klebansky, Boris
    Tanga, Mary J.
    D'Andrea, Annalisa
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (24) : 7454 - 7457
  • [30] Blocking JAK1/JAK2 While Sparing JAK3 Not Only Prevents GvHD but Also Promotes Damaged Tissue Repair
    Ashami, Kidist
    Kim, Sena
    Vij, Ravi
    Ritchey, Julie K.
    Santhanam, Srikanth
    Lim, Sora
    Peterson, Sarah
    Ciorba, Matthew
    DiPersio, John F.
    Choi, Jaebok
    BLOOD, 2019, 134